For the current week, the overall ratings of three pharmaceutical stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Alcobra Ltd.’s (ADHD) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. In Portfolio Grader’s specific subcategories of Earnings Momentum, Equity and Cash Flow, ADHD also gets an F. Shares of the stock are changing hands at twice the rate they were a week ago. To get an in-depth look at ADHD, get Portfolio Grader’s complete analysis of ADHD stock.

Lipocine, Inc. (LPCN) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The stock gets F’s in Earnings Revisions, Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

AcelRx Pharmaceuticals, Inc. (ACRX) experiences a ratings drop this week, going from last week’s C to a D. AcelRx Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The stock also gets an F in Earnings Momentum. As of Feb. 18, 2015, 20.5% of outstanding AcelRx Pharmaceuticals, Inc. shares were held short. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. To get an in-depth look at ACRX, get Portfolio Grader’s complete analysis of ACRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.